Hester Biosciences's total inventories for the quarter that ended in Mar. 2026 was ₹725 Mil. Hester Biosciences's average total inventories from the quarter that ended in Dec. 2025 to the quarter that ended in Mar. 2026 was ₹363 Mil.
In Ben Graham's calculation of Net-Net Working Capital, inventory is only considered worth half of its book value. Hester Biosciences's Net-Net Working Capital per share for the quarter that ended in Mar. 2026 was ₹-243.31.
Days Inventory indicates the number of days of goods in sales that a company has in the inventory.
Hester Biosciences's Days Inventory for the
three
months ended in Mar. 2026 was 170.14.
Inventory Turnover measures how fast the company turns over its inventory within a year.
Hester Biosciences's Inventory Turnover for the quarter that ended in Mar. 2026 was 0.54.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Hester Biosciences's Inventory-to-Revenue for the quarter that ended in Mar. 2026 was 0.36.
Hester Biosciences (BOM:524669) Total Inventories Explanation
Inventory control is an important part of business operation. If a company does not have enough inventory, it may not be able to meet customers' required delivery time. If it has too much inventory, the cost of holding the inventory can be high.
1. In Ben Graham's calculation of Net-Net Working Capital (NNWC), inventory is only considered worth half of its book value.
Hester Biosciences's Net-Net Working Capital Per Share for the quarter that ended in Mar. 2026 is
4. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Hester Biosciences's Inventory to Revenue for the quarter that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Manufacturers with durable competitive advantages have the advantage that the products they sell do not change, and therefore will never become obsolete. Buffett likes this advantage.
When identifying manufacturers with durable competitive advantage, look for inventory and net earnings that rise correspondingly. This indicates that the company is finding profitable ways to increase sales which called for an increase in inventory.
Manufacturers with inventories that spike up and down are indicative of competitive industries subject to boom and bust.
Hester Biosciences Total Inventories Related Terms
Hester Biosciences Total Inventories Historical Data
* Premium members only.
The historical data trend for Hester Biosciences's Total Inventories can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Total Inventories includes the raw materials, work-in-process goods and completely finished goods of a company. It is a portion of a company's current assets.
Hester Biosciences (BOM:524669) has a Total Inventories of ₹725 Mil as of Mar. 2026. The total amount of inventory as recorded on a company's balance sheet. View historical data for Hester Biosciences and its competitors.
Is Hester Biosciences' Total Inventories too high?
Hester Biosciences' current Total Inventories is ₹725 Mil. Overall, Hester Biosciences has a GF Score™ of 73/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Hester Biosciences' Total Inventories compare to ZTS and UTHR?
Hester Biosciences' Total Inventories of ₹725 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Inventories for a Drug Manufacturers company?
A good Total Inventories depends on the Drug Manufacturers industry context. However, Total Inventories should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Inventories mean?
A high Total Inventories can signal that a stock is expensive relative to its fundamentals. The total amount of inventory as recorded on a company's balance sheet. View historical data for Hester Biosciences and its competitors. Hester Biosciences's current Total Inventories is ₹725 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hester Biosciences stock overvalued right now?
Based on GuruFocus' analysis, Hester Biosciences (BOM:524669) is currently considered Modestly Overvalued. The stock's GF Value™ is ₹1,885.73, compared to a current price of ₹2,193.45 — trading 16.3% above its estimated fair value. The current Total Inventories is ₹725 Mil. Hester Biosciences' overall GF Score™ is 73/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Inventories calculated?
Total Inventories is calculated from a company's financial statements. For Hester Biosciences (BOM:524669), the current Total Inventories is ₹725 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Hester Biosciences (BOM:524669) Overvalued in 2026?
Based on GuruFocus' analysis, Hester Biosciences stock appears to be overvalued.
The current stock price of ₹2,193.45 is trading 16.3% above its estimated GF Value™ of ₹1,885.73.
GuruFocus considers Hester Biosciences to be Modestly Overvalued.
Key valuation signals for BOM:524669:
Total Inventories: ₹725 Mil
GF Value™: ₹1,885.73 vs. price of ₹2,193.45 (16.3% above fair value)
No single metric tells the full story. See the BOM:524669 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Hester Biosciences Ltd is an India-based animal healthcare company. It is principally engaged in the manufacturing of veterinary vaccines and trading of veterinary health products such as goat pox vaccine, PPR vaccines, etc. The group has two principal operating and reporting segments, viz. Poultry healthcare and Animal healthcare. Maximum revenue is generated from the Poultry Healthcare segment, which offers various solutions encompassing vaccines, health products, and feed supplements, supported and packaged by its diagnostic services, R&D, quality standards, and field support, to help farmers protect flock health, enhance productivity, and drive long-term farm sustainability. Geographically, it generates maximum revenue within India, and also exports its products to other markets.
73GF Score
Get the complete analysis for BOM:524669
Total Inventories is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:524669 has been successfully added to your 
